Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer

BackgroundSeveral randomized studies have shown that the combination of programmed cell death 1 (PD-1) inhibitor and chemotherapy is efficacious as a treatment for advanced non-small-cell lung cancer (NSCLC). However, in the neoadjuvant setting, there is scarce evidence of the effectiveness and safe...

Full description

Bibliographic Details
Main Authors: Liang Shi, Qiyi Meng, Li Tong, Hongxia Li, Yujie Dong, Chongyu Su, Zhe Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
resectable non-small-cell lung cancer
squamous cell carcinoma
neoadjuvant chemoimmunotherapy
programmed death-1 inhibitors
pathologic response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.956755/full

Similar Items

Similar Items